ANAB vs MRK
ANAB: AnaptysBio is an immunotherapy company generating revenue from blockbuster royalties (Jemperli with GSK, imsidolimab with Vanda) while pursuing its own clinical-stage pipeline for autoimmune and inflammatory diseases. MRK: Global pharmaceutical and vaccine leader with oncology, infectious disease, and animal health franchises, anchored by blockbuster immunotherapy Keytruda.
Side-by-side fundamentals
| Metric | ANAB | MRK | Edge |
|---|---|---|---|
| Price as of 2026-07-22 close | $52.61 | $127.47 | |
| Market cap as of 2026-07-23 | $1.6B | $315.3B | |
| P/E as of 2026-07-23 | n/a | 35.29 | |
| PEG as of 2026-07-23 | n/a | 4.34 | |
| Net margin as of 2026-07-23 | -11.5% | +13.6% | MRK higher |
| Gross margin as of 2026-07-23 | n/a | +78.1% | |
| Operating margin as of 2026-07-23 | +17.6% | +18.2% | MRK higher |
| ROE as of 2026-07-23 | -13.1% | +17.9% | MRK higher |
| ROA as of 2026-07-23 | -7.8% | +7.0% | MRK higher |
| Debt / equity as of 2026-07-23 | 20.69 | 1.07 | MRK lower |
| Revenue growth (YoY) as of 2026-07-23 | +107.7% | +2.9% | ANAB higher |
| Revenue CAGR (3y) SEC XBRL | +183.6% | +3.1% | ANAB higher |
| Dividend yield as of 2026-07-23 | n/a | +2.7% | |
| Dividend streak (yrs) SEC XBRL | n/a | 5 | |
| Beta as of 2026-07-23 | 0.83 | 0.21 | |
| 1-year return as of 2026-07-22 close | +201.1% | +56.2% | ANAB higher |
Fundamentals: Finnhub, as of 2026-07-23. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-22.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.